Trials / Conditions / EGFR-TKI Resistant Mutation

EGFR-TKI Resistant Mutation

8 registered clinical trials studyying EGFR-TKI Resistant Mutation — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lu NCT06363734	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients NCT06071013	China Medical University Hospital	Phase 1 / Phase 2
Active Not Recruiting	Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With E NCT05256290	Black Diamond Therapeutics, Inc.	Phase 1 / Phase 2
Recruiting	Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-po NCT05598528	Second Xiangya Hospital of Central South University	—
Unknown	Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGF NCT02972333	Shandong Cancer Hospital and Institute	Phase 3
Unknown	Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method) NCT02661009	GenoSaber	—
Completed	Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Canc NCT02575560	Qingdao Central Hospital	—
Recruiting	A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment NCT01994057	Sun Yat-sen University	—